drugset / Trial / NCT00751777

Traveler's Diarrhea (TD) Automated Process

NCT00751777 ↗

Phase 2 Completed 120 enrolled Intercell USA, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.

Timeline

Start
2008-09
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject heat-labile enterotoxin of E. coli (LT) Vaccine 37.5 ug Other

Indications

No indication recorded.